CellaVision is paying about $27.7 million for the deal, and is being funded through a combination of cash, cash equivalents, and a loan.
The firm said that the system's automation and flexibility will help centers be more productive within a testing specialty that can require extensive hands-on time.
The agency continues to recommend screening for all individuals ages 15 to 65, and has added its support for preexposure prophylaxis in high-risk populations.
The financing accelerates the development of the Zero Delay plasma preparation system for immediate blood plasma isolation and stabilization at the point of collection.
Orto+ will be market and distribute Todos' TM-B2 test for breast cancer screening in Romania and Austria. The test is CE marked.
The company said it expects revenues from its ePlex analyzers to go up approximately 110 percent year over year for Q4.
The firm has filed for CE marking for the initial MosaiQ IH microarray and anticipates filing for its first serological disease screening microarray during the first half of 2019.
The platform, which Waters introduced last month, uses flow-injection tandem mass spectrometry to enable high-throughput analysis of dried blood spots.
The company's technology uses a drop of blood applied to a biochip to provide a "complete panel" of diagnostic test results within 15 minutes.
The ID Core XT is the second molecular assay approved by the FDA for use in transfusion medicine and the first to report genotypes as final results.